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Trisomy 21Down syndrome (DS) is the most frequent genetic cause of intellectual disability characterized by the pres-
ence of three copies of chromosome 21 (Chr21). Individuals with DS have sufﬁcient neuropathology for a
diagnosis of Alzheimer's disease (AD) after the age of 40 years. The aim of our study is to gain new insights
in the molecular mechanisms impaired in DS subjects that eventually lead to the development of dementia.
We evaluate the PI3K/Akt/mTOR axis in the frontal cortex from DS cases (under the age of 40 years) and DS
with AD neuropathology compared with age-matched controls (Young and Old). The PI3K/Akt/mTOR axis
may control several key pathways involved in AD that, if aberrantly regulated, affect amyloid beta (Aβ) de-
position and tau phosphorylation. Our results show a hyperactivation of PI3K/Akt/mTOR axis in individuals
with DS, with and without AD pathology, in comparison with respective controls. The PI3K/Akt/mTOR de-
regulation results in decreased autophagy, inhibition of IRS1 and GSK3β activity. Moreover, our data sug-
gest that aberrant activation of the PI3K/Akt/mTOR axis acts in parallel to RCAN1 in phosphorylating tau,
in DS and DS/AD. In conclusion, this study provides insights into the neuropathological mechanisms that
may be engaged during the development of AD in DS. We suggest that deregulation of this signaling cascade
is already evident in young DS cases and persist in the presence of AD pathology. The impairment of the
PI3K/Akt/mTOR axis in DS population might represent a key-contributing factor to the neurodegenerative
process that culminates in Alzheimer-like dementia.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Down syndrome (DS), a genetic condition most commonly charac-
terized by the triplication of chromosome 21 (trisomy 21), is the most
frequent chromosomal abnormality that causes neurologic deﬁciencies
worldwide and affects all racial and socioeconomic groups. Life expec-
tancy of the DS population increased signiﬁcantly in the last decades
due to improvement in health care, particularly in younger individuals.
However, increased lifespan is associatedwith an increased incidence of
Alzheimer disease (AD) neuropathology and dementia [1]. Among caus-
ative factors, one of the most accepted hypothesis is centered on the
triplication of the amyloid beta precursor protein (APP) gene, which is
encoded on Chr21 and leads to protein overexpression [2]. In fact, DS
patients show early plaque deposition and other characteristic patho-
logical hallmarks associated with the clinical course of AD [3,4]. The
main difference is the early age of onset of AD pathology in individualscal Sciences “A. Rossi Fanelli”,
e (IT). Tel.: +39 0649910900;
omenico).with DS (40–50 years), with high incidence of clinical symptoms in the
range of 50–60 years of age [5]. A number of studies demonstrated that
the accumulation of amyloid beta (Aβ)-peptide in DS brain can be ob-
served as early as 8–12 years of age [6]. The etiology of AD still remains
obscure and the molecular pathways by which the various pathological
alterations selectively impair cognitive domains related to learning and
memory are far from being clariﬁed. Within this context, by studying
autopsy samples from individuals with DS of various ages provides crit-
ical information regarding AD pathogenesis. Recently, Cenini et al. [7]
demonstrated that Aβ peptide and its small-derived oligomers increase
as a function of age in DS frontal cortex, and this is accompanied by el-
evated protein carbonylation, a marker of oxidative stress. A number of
studies have shown that trisomy-related increase of oxidative stress
might be involved in different aspects of DS phenotypes [1,8–11]. In
linewith these studies, our group reported that DS brain, prior to signif-
icant AD pathology, shows an early disturbance of the proteostasis net-
work possibly linked to increased oxidative stress conditions and also
autophagy impairment [12]. A decreased ratio of LC3 II/I, an index of
autophagosome formation, was demonstrated thus suggesting that de-
crease of autophagic ﬂux occurs early in DS.
Considering the current notion that autophagy plays a critical role in
multiple pathological lesions of AD [13–16], we focus our attention on
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the development of Alzheimer-like neurodegeneration in DS individ-
uals. Indeed, dysfunction of the autophagy-lysosomal system also
contributes to Aβ accumulation, the formation of tau oligomers, and in-
soluble aggregates, and in contrast induction of autophagy enhances the
clearance of both soluble and aggregated forms of Aβ and tau proteins
[17].
The autophagy cascade is regulated by PI3K (phosphoinositide3-
kinase)/Akt/mTOR axis, which plays a central role in controlling pro-
tein homeostasis. The normal on/off switching of the PI3K/Akt signaling
pathway, particularly by its major activators insulin and IGF-1 (insulin-
like growth factor-1), integrates physiological responses fundamental
to healthy aging and longevity. Several studies showed aberrant and
sustained activation of neuronal PI3K/Akt/mTOR signaling in AD brain
[18–20]. In parallel, the activation of PI3K/Akt/mTOR is reported to
cause insulin receptor substrate 1 (IRS1) inhibition, disabling normal
activation of PI3K/Akt by insulin, IGF-1 and other growth factors. An in-
creasing number of studies demonstrated that memory alterations
could be linked to abnormalities in circulating insulin levels and/or de-
fects in insulin signaling pathways in AD [20–24]. Furthermore, a
prolonged peripheral hyperinsulinemia could impair the blood brain
barrier and insulin transport into CNS, thus affecting insulin receptor
(IR) activity and culminating in a brain insulin resistance that could ac-
count for the lower insulin levels in CSF of AD patients. It is well-known
that diabetes mellitus has a higher prevalence in DS than in the general
population [25] and a relationshipmay exist between insulin resistance
and the development of AD in the typical, elderly, adult population and
in DS.
Based on these observations, the aim of the current study was to in-
vestigate the status of the PI3K/Akt/mTOR pathway in the frontal cortex
from DS autopsy cases without AD neuropathology (typically under the
age of 40 years) and DS with AD neuropathology. Both DS groups were
compared with appropriate non-DS, healthy age-matched controls. We
tested the hypothesis that the overactivation of PI3K/Akt/mTOR
sustained by increased Aβ levels may, directly or indirectly, uncouple
insulin response. Considering the cross-talk between insulin resistance
and cognitive defects, we hypothesize that alteration of PI3K/Akt/
mTOR pathways may play a role in the development of dementia in
DS, before clinical manifestation AD neuropathology.
2. Materials and methods
2.1. Subjects
DS and young or older control cases (without AD neuropathology)
were obtained from the University of California-Irvine-ADRC Brain
Tissue Repository, the Eunice Kennedy Shriver NICHD Brain and Tissue
Bank for Developmental Disorders, and the University of Kentucky
Alzheimer's Disease Center. Table 1 shows the characteristics of the
included cases. DS cases were divided into two groups, with or without
sufﬁcient pathology for a neuropathology diagnosis of AD. All caseswith
both DS and AD were over the age of 40 years. Thus for the current
study, controls were split into two groups, either less than or equal to
40 years or older than 40 years at death. The post mortem intervalTable 1
Autopsy case demographics. A complete set of information is reported as supplementary
material (extensive demographic data are reported in sup. Table 1).
Groups n Gender (M/F) Age PMI
(avg. ± SD) (avg. ± SD)
Control Y 8 4/4 24.8 ± 11.6 12.1 ± 4.71
DS 8 6/2 23.3 ± 16.8 13.4 ± 2.13
Control O 8 5/3 57.2 ± 7.6 11.3 ± 6.90
DS/AD 8 5/3 59.5 ± 3.2 4.2 ± 1.57⁎
⁎ Signiﬁcantly shorter than the other 3 groups.(PMI) was different across groups with DS/AD having a signiﬁcantly
shorter value in respect to the other groups (Table 1). The subgroup
used in this study was selected in order to maintain homogenous age
and gender inside the groups and is part of the entire cohort used in a
previous experiment to investigate insoluble Aβ and total oxidation as
a function of age in DS [7].
2.2. Sample preparation for Western blots
Frontal cortex tissue 20mg (n= 8 per group) from controls (young
and old), DS, andDS/ADwere thawed in RIPA buffer (pH 7.4) containing
50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.25% sodium
deoxycholate,1 mM EDTA, 0,1% SDS, 1 mM PMSF, 1 mM NaF and 1 mM
Na3VO4. Brains were homogenized by 20 passes of a Wheaton tissue ho-
mogenizer, and the resulting homogenate was centrifuged at 14,000 ×g
for 10 min to remove cellular debris. The supernatant was extracted to
determine the total protein concentration by the Bradford assay (Pierce,
Rockford, IL).
2.3. Western blot
For Western blots, 30 μg of proteins (CTR and DS) was separated by
12% and 7.5% SDS-PAGE using Criterion Gel TGX Stain free (Bio-Rad)
and blotted into a nitrocellulose membrane (Bio-Rad, Hercules, CA,
USA). Before blotting the gel imagewith protein total loadwas acquired
to normalize blot analysis. Membranes were blocked with 3% bovine
serum albumin in T-TBS and incubated for 1 h and 30min at room tem-
perature with primary anti-bodies: p-44/42 MAPK (Thr202/Tyr204)
(1:2000), mTOR (1:1000), p-mTOR (Ser2448) (1:1000), Akt and p-Akt
(Ser473) (1:1000), p-70S6K (Thr389) (1:1000), IRS1 and p-IRS1 (Ser307)
(1:1000) from Cell Signaling; LC3 II/I (1:500) from NOVUS; p-mTOR
(Ser2448), p-Tau (Ser404) (1:1000), GSK3 β and p-GSK3β (Ser9)
(1:1000) from Santa Cruz; RCAN 1 and DYRK1A (1:1000) from Sigma-
Aldrich. After three washes with T-TBS, the membranes were incubated
for 1 h at room temperature with secondary antibody horseradish
peroxidase-conjugated anti-rabbit or anti-mouse IgG (1:5000; Sigma-
Aldrich, St Louis, MO, USA). Membranes were developed with the
Super Signal West Pico chemiluminescent substrate (Thermo Scientiﬁc,
Waltham, MA, USA) acquired with Chemi-Doc MP (Bio-Rad) and
analyzed using Image Lab software (Bio-Rad) that allow the normal-
ization of speciﬁc protein signal with proteins total load obtained by
ﬂuorescent detection of monodimensional proteome on TGX stain
free gels (Figs. 1, 2, 3, 5 and 6).
2.4. Statistical analysis
Data are expressed as mean ± SD of 8 independent samples per
group. All statistical analyses were performed using a non-parametric
one-way ANOVA with post hoc Bonferroni t-test. p b 0.05 (*) was
considered signiﬁcantly different from control. Since DS/AD PMI is sig-
niﬁcantly different in comparison to the other three groups we per-
formed linear regression analyses between each experimental data vs.
PMI in order to test if our results were affected by PMI variable. More-
over, we correlated experimental data from CTR group (CTR Y and
CTR O) and DS group (DS and DS/AD) with age to analyze the effects
of age variations. Finally, to determine how our data are affected by
genotype (DS) and age and the interaction of such factors we accom-
plished a 2-way ANOVA analysis. All statistical analysis was performed
using GraphPad Prism 5.0 software.
3. Results
3.1. PI3K/Akt pathway
In order to evaluate if the PI3K/Akt pathway was impaired in the
brains of DS and DS with AD pathology cases, we analyzed by Western
Fig. 1. PI3K p85 phosphorylation levels (Tyr508) and expression levels ratio (panel A), Akt
phosphorylation levels (Ser473) and expression levels ratio (panel B) and MAPK 44/42
(ERK1/2) phosphorylation levels normalized on expression levels (panel C) in the brain
frontal cortex of controls and DS cases. Brain samples of the frontal cortex were assayed
byWestern blot as described in the Materials and methods section. Densitometric values
shown in the histograms are the mean of 8 individual cases per each experimental group
normalized per total protein load and are given as percentage of young control, set as
100%. Above in the ﬁgure a representative blot image (with 4 of 8) protein bands is
shown. *p b 0.05; §p = 0.07.
Fig. 2. mTOR phosphorylation levels (Ser2448) and expression levels ratio (panel A),
p70S6K phosphorylation levels (Thr389) and expression levels ratio (panel C) and
LC3 II/I expression levels ratio (panel B) in the brain frontal cortex of controls and
DS cases. Densitometric values shown in the histograms are the mean of 8 individual
cases per group normalized per total protein load and are given as percentage of Con-
trol, set as 100%. Above in the ﬁgure a representative blot image with (with 4 of 8)
protein bands is shown. *p b 0.05.
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(Fig. 1A & B). PI3K is a heterodimer formed by a p110 catalytic subunit
and a p85 regulatory subunit. The most highly expressed regulatory
subunit is p85α, and one of two domains binds preferentially to phos-
phorylated tyrosine residues [26]. In this pathway the increased phos-
phorylation of PI3K induces an increased level of phosphorylated Akt.
Akt is activated by phospholipid binding, by phosphorylation within
the carboxy-terminus at Ser473, and by activation loop phosphorylation
at Thr308 by PDK1 [27]. We ﬁrst determined that PMI was not a signiﬁ-
cant contributor to the outcome and a linear regression analysis of both
p-PI3K and p-Akt values with PMI showed no signiﬁcant p value (R2 =
0.073, p = 0.132 for p-PI3K; R2 = 0.053, p = 0.204 for p-Akt) indicat-
ing no relation of PI3K or Akt phosphorylation with PMI variation.Increased phosphorylation of PI3K p85α subunit (Tyr508) normalized
on protein expression (Fig. 1A) in both DS and DS/AD individuals com-
paredwith age-matched CTRwas found, in the latter the increase of 80%
was statistically signiﬁcant (*p b 0.05) while in the comparison DS vs.
CTR Y was close to signiﬁcance (§p = 0.07). The phosphorylation of
Akt (Ser473) (normalized on protein expression level) was signiﬁcantly
increased in DS vs. CTR Y (215%, p b 0.05) 50% and in DS/AD vs. CTR O
(285% vs. 113%, *p b 0.05) (Fig. 1B). No signiﬁcant differences were
found between DS and DS/AD groups for both p-PI3K and p-Akt values.
Further, The linear regression analyses of CTR cases and DS cases
subgroups separately and age showed no signiﬁcant correlations be-
tween p-PI3K (CTR p= 0.4, R2= 0.048; DS p= 0.14, R2= 0.14) and
p-Akt (CTR p= 0.47, R2= 0.036; DSp=0.4, R2= 0.049) and age. Over-
all, when including all DS and control cases, protein phosphorylation
values were not associated with age variable (R2 = 0.074, p = 0.131
Fig. 3. IRS1 phosphorylation levels (Ser307) (panel A) and IRS1 expression levels (panel B)
in the brain frontal cortex of controls and DS cases. Densitometric values shown in the his-
tograms are the mean of 8 individual cases per group normalized per total protein load
and are given as percentage of Control, set as 100%. In panel C the histogram represent
the average per group of phosphorylation values normalized for expression values, the
normalization was performed on each single subject analyzed. Above in the ﬁgure a rep-
resentative blot image with (with 4 of 8) protein bands is shown. * p b 0.05.
Table 2
2-Way ANOVA analysis data.
Target of analysis 2-Way ANOVA
Age (young–old) Genotype (DS–DS/AD) Interaction
% of tot var. p value % of tot var. p value
p-Akt 8.26 *0.021 52.09 *b0.0001 0.532
p-PI3K 11.75 *0.020 29.30 *0.0006 0.137
MAPK p44 5.73 0.286 25.84 *0.0357 0.118
MAPK p42 4.69 0.385 20.73 0.082 0.355
p-mTOR 18.57 0.113 34.29 *0.042 1.000
LC3 II/I 7.15 0.189 31.88 *0.010 0.880
p-p70S6K 9.92 *0.033 32.77 *0.0004 0.377
IRS1 28.18 *0.002 1.33 0.470 0.526
p-IRS1 50.33 *b0.0001 21.08 *0.003 0.799
p-IRS1/IRS1 4.74 0.304 26.55 *0.023 0.576
p-tau 7.24 0.079 68.65 *b0.0001 0.662
p-GSK3β 1.45 0.466 62.14 *0.0004 0.162
RCAN1 14.10 *0.016 64.23 *b0.0001 0.914
DYRK1A 1.56 0.480 3.76 0.275 0.085
Bold values indicates values that are signiﬁcant in 2-way ANOVA analysis.
* p b 0.05.
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analysis (Table 2) shows that age signiﬁcantly accounts for 8.26% (p =
0.021) and 11.75% (p = 0.020) of the total variance of p-Akt and p-
PI3K, respectively, while genotype signiﬁcantly accounts for 52.09%
(p b 0.0001) and 29.30% (p = 0.0006).
3.2. ERK1/2 pathway
MAPK 44/42 (ERK1/2) is a kinase activated in response to insulin
signaling that regulates mTOR and the autophagy pathway and
exhibits a negative feedback modulation of IRS1 activity by phos-
phorylating IRS inhibitory residue [28]. Thus, ERKs aberrant activity
could be involved in mTOR hyperactivation, autophagy impairment
and IRS mediated insulin resistance in DS and AD brain. Several genes
mapping to chromosome 21 interact with MAPK, and also MAP kinase
44/42 is one of the several kinases involved in pathological tau
hyperphosphorylation. Linear regression analyses show that MAPK
44/42 phosphorylation is not dependent on PMI (R2 = 0.002, p =
0.860 for MAPK 44; R2 = 0.020, p = 0.598 for MAPK 42) s. In addition,
the linear regression analyses of CTR cases and DS cases separately andage did not show signiﬁcant correlations with MAPK p44 (CTR p =
0.19, R2 = 0.26; DS p = 0.45, R2 = 0.095). Our data demonstrate
the aberrant phosphorylation of MAPK 44 (ERK 1), with a signiﬁcant
increase (40%) in DS brain compared to age-matched CTR but not in DS
with AD (Fig. 1C) when compared to CTR O. No signiﬁcant differences
were found in the comparison of DS and DS/AD groups. The 2-way
ANOVA analysis (Table 2) shows that age and genotype have no sig-
niﬁcant effect on MAPK p42 data, while for MAPK p44 genotype but
not age signiﬁcantly accounts for 25.84% (p= 0.035) of the total var-
iance. We suggest that MAPK 44 activation in DS could contribute
with PI3K/Akt to the aberrant regulation of mTOR activity and
autophagosome formation.
3.3. mTOR activation and inhibition of autophagosome formation
A major downstream target of the PI3K/Akt pathway is mTOR.
Consequently we analyzed the expression levels and phosphoryla-
tion (Ser2448) of mTOR. mTOR did not show any signiﬁcant difference
in expression between the two groups of comparison. In contrast the
extent of phosphorylated mTOR showed increased levels in both DS
(about 180%, p b 0.05) and DS/AD (about 150%, p b 0.05) compared
to age-matched controls (Fig. 2A). A linear regression analyses
showed no association of all groups between p-mTOR and PMI values
(R2 = 0.058, p = 0.447); 2-way ANOVA analysis of mTOR data show
that genotype signiﬁcantly accounts for 34.29% (p = 0.042) of the
total variance while age has no signiﬁcant effect (Table 2); however,
p-mTOR signal was very faint and not easy to analyze (Fig. 2). Thus,
to conﬁrm mTOR activation we analyzed p70S6K phosphorylation
(Thr389), a direct downstream target of mTOR activity that is often
employed to indirectly measure mTOR phosphorylation. The data
show increased p-p70S6K (normalized on protein expression) in
DS vs. CTR Y (about 40%, p b 0.05) and in DS/AD vs. CTR O (about
60%, p b 0.05) but not in DS vs. DS/AD (Fig. 2B). mTORdirectly regulates
the autophagy pathway, suggesting that increased PI3K/Akt/mTOR ac-
tivity contributes to decreased autophagic ﬂux observed in DS and AD
subjects. The analysis of LC3II/I, an index of autophagosome formation,
conﬁrms our hypothesis, showing a decreased LC3 II/I ratio early in DS
brain (near 30% lower levels as compared with age-matched controls,
p b 0.05) and further decreased levels in DS with AD (about 45%
lower, p b 0.05) in comparison to their respective age-matched con-
trols. No signiﬁcant differences were found in the comparison of DS
and DS/AD groups (Fig. 2C). Both p70S6K phosphorylation levels and
LC3 II/I ratio of all groups analyzed together by linear regression show
no relation with PMI differences (R2 = 0.048, p = 0.224 for p-
p70S6K; R2 = 0.015, p = 0.605 for LC3 II/I) or age differences (R2 =
Fig. 4. In panels A and B linear regression graph of both total IRS1 expression (IRS1) levels
and total phosphorylation (p-IRS1) levelswith age are shown. In panel C the linear regres-
sion analysis of IRS1 expression levels and age in CTR and DS cases subgroups is shown. In
panel D the linear regression analysis of IRS1 phosphorylation levels and age inCTR andDS
cases subgroups is shown.
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among the groups. The linear regression analyses of CTR cases and DS
cases separately with age showed signiﬁcant correlations of p-p70S6K
only in CTR cases (p = 0.04, R2 = 0.25) but not in DS cases (p =0.26,
R2 = 0.087). In contrast, LC3 data showed no signiﬁcant correlation
with age within each group (CTR p = 0.63, R2 = 0.029; DS p =0.098,
R2 = 0.30). 2-Way ANOVA analysis of p-PI3K demonstrates that
age signiﬁcantly accounts for 9.22% (p= 0.033) of the total variance
while genotype signiﬁcantly accounts for 32.77% (p = 0.0004). LC3
II/I analysis shows that genotype signiﬁcantly accounts for 31.88%
(p = 0.01) of the total variance while age has no signiﬁcant effect
(Table 2). Our results shown in Fig. 2B are consistent with our previ-
ous work where we demonstrate the impairment of autophagosome
formation in DS compared to CTR Y [12] and now present novel data
showing a comparable decreased levels of autophagosome function
in DS/AD when compared to older age-matched controls.
3.4. IRS1 inactivation is induced by PI3K/Akt pathway impairment
PI3K/Akt is closely related to insulin signaling through insulin
substrate receptor (IRS1). PI3K is directly phosphorylated by IRS1
regulating PI3K/Akt cascade in response to insulin levels. In contrast,
sustained PI3K/Akt activation inhibits IRS1 activity by negative feed-
back through the activation of mTOR and p70S6K that phosphorylate
IRS1 on its inhibitory domain (Ser307) [18]. To evaluate the levels of
IRS1 inactivation in the four groups, we analyzed the expression
levels of IRS1, the phosphorylation levels of IRS1 at Ser307 and the
ratio of the two. Phosphorylated IRS1 was increased ~30% in DS com-
pared to CTR Y and higher in DS/AD compared to CTR O (p b 0.05;
Fig. 3A). DS/AD had lower levels of p-IRS1 compared to DS (about
55%; p b 0.05). IRS1 expression levels are increased in DS compared
with CTR Y (40%, p b 0.05) but no differences were observed be-
tween DS/AD and CTR O (Fig. 3B). The ratio of phosphorylated IRS1
to total IRS1 showed a signiﬁcant increase between DS and CTR Y
(126%, p b 0.05) and 153% (p b 0.05) higher in DS/AD compared to
CTR O (Fig. 3C). There were no differences between DS and DS/AD.
The linear regression analysis shows that IRS1 expression decreased
overall as a function of age (R2 = 0.198, p = 0.010) (Fig. 4A & B), in-
dependent of the presence of DS. Interestingly, the linear regression
analyses of CTR cases and DS cases separately with age showed a
strong correlation for IRS1 phosphorylation levels in both CTR and
DS (CTR p = 0.025, R2 = 0.30; DS p = 0.026, R2 = 0.30; Fig. 4C),
while IRS1 expression levels were signiﬁcantly correlated with age
only for CTR cases (CTR p = 0.017, R2 = 0.34; DS p = 0.19, R2 =
0.12; Fig. 4D). 2-Way ANOVA analysis of IRS1 expression shows that
age signiﬁcantly accounts for 28.18% (p = 0.002) of the total variance
while genotype has no signiﬁcant effect. The analysis of p-IRS shows
that age signiﬁcantly accounts for 50.33% (p b 0.0001) of the total vari-
ance while genotype signiﬁcantly accounts for 21.08% (p = 0.003) of
the total variance (Table 2). Overall, when IRS1 phosphorylation values
are normalized on expression values the 2-way ANOVA analysis shows
that genotype signiﬁcantly accounts for 26.55% (p= 0.023) of the total
variance while age has no signiﬁcant effect (Table 2). Both IRS1 expres-
sion and phosphorylation levels analyzed by linear regression show no
relationwith PMI variations among the groups (R2= 0.002, p= 0.798;
R2 = 0.016, p = 0.608).
3.5. p-Tau and tau kinases (GSK3β, RCAN1 and DYRK1A)
The hyperphosphorylation of tau in brains of DS cases has been
demonstrated by several authors [4], and our data conﬁrm that
both DS vs. CTR Y and DS/AD vs. CTR O show increased levels of tau
phosphorylation (about 200%, p b 0.05) at Ser404 (Fig. 5C; D). The
comparison of DS/AD and DS groups shows no signiﬁcant differ-
ences. Several proteins are involved in tau phosphorylation such as
GSK3β and DYRK1A that function as kinases or RCAN1 through theinhibition of calcineurin [29–32]. Akt is known to directly regulate
GSK3β by phosphorylation of its inhibitory serine residue (Ser9).
Therefore, we measured the levels of GSK3β expression and of
GSK3β phosphorylated at Ser9 in our groups. GSK3β expression
levels were higher in DS cases compared to each appropriate age-
matched CTR group reaching signiﬁcance in DS/AD vs. CTR O
(about 30%, p b 0.05), no signiﬁcant differences were found between
DS and DS/AD groups (Fig. 5A). GSK3β inhibitory phosphorylation
levels were signiﬁcantly increased in DS vs. CTR Y (177%, p b 0.05)
and in DS/AD vs. CTR O (150%, p b 0.05) suggesting increased inacti-
vation of GSK3β even when normalized on protein expression
(Fig. 5B&C) in DS overall. A comparison between DS and DS/AD
groups showed no signiﬁcant differences, and interestingly, values
are very similar between these two groups. As previously noted tau
phosphorylation could be induced directly or indirectly by DYRK1A
and RCAN1, which are both encoded on chromosome 21. Our analy-
sis of DYRK1A and RCAN1 expression levels demonstrated elevated
expression levels of DYRK1A in DS vs. CTR Y (about 40%, p b 0.05)
Fig. 5. GSK3β (Ser9) phosphorylation levels (panel A), GSK3β expression levels (panel B),
the GSK3β phosphorylation/expression ratio (panel C) and tau phosphorylation levels
(Ser404) (panel D) in the brain frontal cortex of controls and DS cases. Densitometric
values shown in the histograms are the mean of 8 individual samples per group normal-
ized per total protein load and are given as percentage of Control, set as 100%. Above in
the ﬁgure a representative blot image with protein bands is shown. *p b 0.05.
Fig. 6.DYRK1A (panel A) and RCAN1 (panel B) expression levels in the brain frontal cortex
of controls and DS cases. Densitometric values shown in the histograms are the mean of 8
individual samples per group normalized per total protein load and are given as percent-
age of Control, set as 100%. Above in the ﬁgure a representative blot image with protein
bands is shown. *p b 0.05. In panels C and D the correlation analysis of RCAN1 with p-
tau (graph on the left) and GSK3β (graph on the right) are shown.
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increased levels of DYRK1A when compared to DS/AD (Fig. 6A).
Our data demonstrate increased expression levels of RCAN1 in both
DS vs. CTR Y (about 30%, p b 0.05) and in DS/AD vs. CTR O (about
45%, p b 0.05) but not in DS vs. DS/AD, supporting the likely involve-
ment of this protein in phosphorylating tau (Fig. 6B) in DS overall. In-
deed, RCAN1 levels positively correlate with p-tau levels (p= 0.031,
r = 0.538; Fig. 6C), while DYRK1A does not (p = 0.39, r = 0.22). In
addition RCAN1 expression levels correlate positively with GSK3β
levels (p = 0.013, r = 0.73) (Fig. 6D). The extent of tau phosphory-
lation, GSK3β phosphorylation, DYRK1A and RCAN1 expression levels
is independent of PMI (R2 = 0.0003, p = 0.944 for p-tau; R2 = 0.016,
p = 0.636 for p-GSK3β; R2 = 0.060, p = 0.176 for DYRK1A; R2 =
0.070, p = 0.319 for RCAN1) or age variations (R2 = 0.071, p = 0.315
for p-tau; R2 = 0.017, p = 0.624 for p-GSK3β; R2 = 0.063, p = 0.173
for DYRK1A; R2 = 0.163, p = 0.119 for RCAN1) among all groups ana-
lyzed together. Moreover, the linear regression analyses of CTR cases
and DS cases separately with age showed no signiﬁcant correlation for
p-tau (CTR p= 0.26, R2= 0.19; DS p= 0.64, R2= 0.037), a signiﬁcant
correlation for p-GSK3β only in CTR cases (CTR p = 0.028, R2 = 0.57;DS p = 0.7, R2 = 0.026), no signiﬁcant correlation for DYRK1A
(CTR p = 0.67, R2 = 0.012; DS p = 0.62, R2 = 0.017) and signiﬁcant
correlations for RCAN1 in CTR cases (CTR p = 0.039, R2 = 0.53; DS
p = 0.16, R2 = 0.29) but not in DS cases. 2-Way ANOVA analysis
demonstrates that for p-tau, genotype signiﬁcantly accounts for
68.65% (p b 0.0001) of total variance while age has no signiﬁcant ef-
fect; for p-GSK3β, genotype signiﬁcantly accounts for 62.14% (p =
0.0004) of total variance while age has no signiﬁcant effect; for
RCAN1, age signiﬁcantly accounts for 14.10% (p = 0.016) of total
variance while genotype accounts for 64.23% (p b 0.0001); for
DYRK1A age and genotype have no signiﬁcant effect (Table 2).
4. Discussion
The brains of individuals with DS are characterized by an age-
dependent deposition of Aβ as a consequence of increased APP [3,33,
34]. Similar to AD, Aβ accumulation in DS is associated with enhanced
oxidative stress [35], indexed, in both DS and DS/AD specimens, by
markers of protein oxidation (protein bound-HNE and protein car-
bonyls) and increased oxidative modiﬁcation of target proteins mostly
belonging to the proteostasis network [1,7,36]. Taken together, these
ﬁndings suggest that AD neuropathology develops in an age-
associated manner in DS and provide useful insights into the earliest
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was to test the hypothesis that disturbance of PI3K/Akt/mTOR axis
may be involved in the development of AD in DS population.
Several studies showed an aberrant and sustained activation of
neuronal PI3K/Akt/mTOR signaling in the early stages of AD [37,
38]. Increased Akt activation and its altered subcellular localization
have been described in hippocampal and cortical neurons of AD
brain [39–42]. Aβ species, have been described to interact and
over-activate the PI3K/Akt/mTOR axis inducing resistance to its
major activators, insulin and IGF-1 [18,20]. Our data are consistent
with the current literature demonstrating that PI3K (p85 subunit)
is aberrantly phosphorylated in DS and DS/AD compared to age-
matched CTR (Fig. 3A). As well, Akt phosphorylation (Ser473) is sig-
niﬁcantly increased in DS and in DS/AD compared to age-matched
controls (Fig. 1B). Accordingly, altered phosphorylation of Akt has
also been observed in Ts65Dn and Ts1Cje mice models of DS [43,
44]. The link between Aβ production and PI3K/Akt overactivation is
also suggested by the fact that in the absence of Aβ, decreased insulin
signaling results in down-regulation of the PI3K/Akt pathway [45,
46]. In order to gain insights into the contribution of Aβ-related
PI3K/Akt overactivation, we analyzed the molecular events triggered
by such aberrant regulation. The varied cellular functions of PI3K-Akt
are reﬂected in the diversity of its downstream targets: mTOR and
S6K1 kinases are among their main downstream effectors [18,21,28].
Previous studies demonstrated that mTOR phosphorylation by Akt
and Aβ is increased in AD brain [23,47,48]. In this study we measured
the activation of mTOR by the analysis of the extent of its phosphoryla-
tion and of one of its main targets, p70S6K, showing that mTOR is
hyperactivated in DS and DS/AD compared to age-matched controls
(Fig. 2A & B). As expected, mTOR activity is aberrantly increased in DS
overall, independent of the presence of AD neuropathology.
In parallel, increased phosphorylation of mTOR inhibits autophagy
through phosphorylation of the ULK1-Atg13-FIP200 complex and
through the regulation of lysosomal function. Autophagy is one of the
major intracellular proteolytic systems in which components of the cell
are degraded in lysosomes/vacuoles and recycled, and itmay be regarded
as a protective process [14,49–51].Wehypothesized that increasedmTOR
activity, mediated by Aβ-dependent Akt hyper activation, contributes to
decreased autophagy seen in DS and AD subjects. Indeed, a decreased
LC3II/I ratio, an index of autophagosome formation, occurs already in
young DS brain and persists in DS/AD brain (Fig. 2C). In our previous
work, we demonstrated the oxidation of speciﬁc components of the pro-
tein degradative pathways (e.g. proteasome, autophagy) in DS cases [12].
The PI3K/Akt/mTOR axis is directly under the control of IRS1, the
major insulin receptor substrate, which through Tyr-phosphorylation
transmits insulin action. This signaling cascade is ﬁnely regulated by a
negative feedback mechanism that suppresses Akt activity in case of a
permanent activation of mTOR/p70S6K signal [52–54]. The negative
feedback mechanism acts through mTOR-mediated phosphorylation
of IRS1 at Ser307, the best studied inhibitory residue that causes IRS1 in-
activation, by disrupting IRS1 binding to IR, inhibiting its tyrosine phos-
phorylation, and directing IRS1 towards proteasome degradation [21].
The uncoupling of insulin signaling and PI3-K/Akt/mTOR axis by IRS1
inactivation represents one of the major causes of insulin resistance
[45,46]. Signiﬁcant evidence indicates that IRS1 is phosphorylated at in-
hibitory serine residues (Ser307) by increased Akt-mTOR-p70S6K activ-
ity in AD neurons leading them to become totally resistant to both
insulin and IGF-1 [55–57]. In addition, insulin resistance in AD might
also be stimulated by Aβ monomers and soluble oligomers that bind
to IRs, induce IR internalization in neurons and remove IR from den-
drites [55,58–61], or inactivate IRS1 through the activation of JNK via
TNFα [62,63]. Our data in the frontal cortex fromDS and DS/AD autopsy
cases shows higher levels of phosphorylation of 11 inhibitory serine
residue (Ser307) compared to their respective age-matched CTR
(Fig. 3A&C). Moreover, IRS1 levels and its phosphorylation are age-
dependent, consistent with the notion that insulin signaling decreasesin the elderly population [56]. However, the rate of IRS1 inhibition
(measured as p-IRS1/IRS1) followed the same trend already described
for the upstream effectors of the insulin signaling cascade (e.g. p-AKT,
p-mTOR), conﬁrming the alteration in DS cases in comparison to CTR
cases.
MAPK 44/42 (ERK1/2) is activated in response to insulin signaling
and regulates mTOR and autophagy pathways through the inhibition
of TSC 1/2 exhibiting a negative feedback modulation of IRS1 inhibi-
tory residue [20,21,28]. Our data demonstrate the aberrant phos-
phorylation of ERK1 in DS compared to age-matched CTR but not in
DS with AD (Fig. 1C). These results parallel the increased IRS1 inhibi-
tion that we observed in DS andmay suggest that theMAPK pathway
is altered in young DS cases, possibly contributing to the attenuated
insulin signaling. Moreover, ERK1 activation in DS could contribute
with PI3K/Akt to the aberrant regulation of mTOR activity and
autophagosome formation [28].
Interestingly, PI3-K/Akt/mTOR signaling is considered a primary
candidate to transmit pathophysiological responses from Aβ to tau.
The up-regulation of p70S6K was found to be associated with the ac-
cumulation of hyperphosphorylated tau in NFT in AD [47,64] and the
sustained activation of PI3K/Akt/mTOR, Aβ-dependent or not, was
shown to directly impact tau hyperphosphorylation [18,20,65–67].
Akt inhibits GSK3β, a major candidate kinase involved in tau
hyperphosphorylation [68,69]. In line with these notions, Akt in-
duced phosphorylation of GSK3β at Ser9, by insulin/IGF-1, inhibiting
tau phosphorylation in vitro [70,71]. Although the role of GSK3β in
tau pathologies has yet to be clearly deﬁned, a number of recent studies
have provided evidence supporting the inactivation of GSK3β in AD
thus uncoupling its “proposed” role as a tau kinase [18]. Similarly,
data from old TC1 mice, a model of trisomy21, also showed increased
phosphorylation of GSK3β at Ser9 concomitantwith increased tau phos-
phorylation [65]. Our data are in line with these results, showing in-
creased tau hyperphosphorylation (Fig. 5D) combined with PI3K/Akt/
mTOR axis hyperactivation and GSK3β inhibition, as indexed by in-
creased phosphorylation at Ser9 in DS overall. However, GSK3β protein
levels were higher only in DS/AD compared with CTRO, possibly due to
overall lower GSK3β in CTR O (Fig. 5A). In previous studies, the overex-
pression of GSK3β was observed in cells treated with Aβ [32], and it is
likely that its up-regulation could be a compensatory mechanism
against reduced activity. Interestingly, levels of active (Tyr216) and inac-
tive (Ser9) GSK3β were reported to be simultaneously increased in AD
patients, suggesting that the regulation of both inhibitory and stimula-
tory inputs of GSK3βmight be impaired [23].
Overall, these ﬁndings led to hypothesize that in the context of DS
pathology tau hyperphosphorylation does not necessarily require
GSK3β, but may be induced by the overexpression of speciﬁc genes,
as a consequence of trisomy. Among such candidates, DYRK1A and
RCAN1 have been proposed to mediate hyperphosphorylation of
tau, and the increased expression and activity of both proteins have
been reported in DS and AD [29–31,72–74]. We found increased ex-
pression of DYRK1A in DS but not in DS/AD compared to CTR
(Fig. 6A). Further, there was a lowering of DYRK1A levels in DS/AD
relative to DS alone. Interestingly, higher DYRK1A levels are associat-
ed with higher levels of phosphorylated, soluble tau in DS without
AD neuropathology but not in DS/AD cases. These results suggest
that DYRK1A may contribute to tau phosphorylation in young DS
subjects but it might not be directly associated with AD pathology.
As regard RCAN1, it may play a role due to its chronic overexpression
in DS as well as in AD [29,30]. RCAN1 is involved in binding and reg-
ulating calcineurin activity and, once overexpressed triggers tau
hyperphosphorylation and the formation of NFT [32,75]. Moreover,
calcineurin inhibition can decrease the proteasome-related degradation
of tau [29,30,75,76]. We found increased levels of RCAN1 in DS and
DS/AD parallel to higher levels of tau phosphorylation (Fig. 6B&C).
Intriguingly, RCAN1 overexpression reported could lead to increased
GSK3β expression and activity [32]; in our system we observe that
Fig. 7. Putative scenario of the pathological role of PI3K/Akt/mTOR cascade in DS and DS/AD individuals, with main focus on proteins that might contribute to the reduction of insulin sig-
naling and to the increase in tau phosphorylation.
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expression levels (Fig. 6D).
5. Conclusion
In summary, our results show a hyperactivation of the PI3K/Akt/
mTOR axis in the brains of DS with or without AD pathology in com-
parison to their respective age-matched CTR. The PI3K/Akt/mTOR
deregulation may result in: i) decreased autophagy ﬂux possibly
contributing to Aβ deposition. Accordingly, our data onmTOR activa-
tion suggests its involvement, together with the oxidation/dysfunc-
tion of a number of autophagy components already demonstrated
by our previous studies, into the decreased autophagosome forma-
tion reported in DS and DS/AD; ii) decreased IRS1 activity that repre-
sents one of the best-characterized events leading to insulin
resistance. DS with AD and AD subjects undergo insulin resistance
during their life as a consequence of the alteration of several, mostly
unknown, molecular mechanisms [25,56]. The alteration of mTOR
pathway could represent an important link between Aβ and insulin
signaling, providing new insights into the relationship between in-
sulin resistance and incidence of AD; iii) decreased GSK3β activity,
which is phosphorylated on its inhibitory serine residue when
PI3K/Akt/mTOR axis is hyperactivated. GSK3β is closely related to
tau hyperphosphorylation and its alteration has been demonstrated
in AD. The inhibition of GSK3β by Akt kinases activity is counteracted
by protein overexpression raising doubt on the effective role of
GSK3β in DS/AD as solely responsible for tau hyperphosphorylation
occurring in DS. In addition, our data suggest that PI3K/Akt/mTOR
axis aberrant activation acts in parallel to DYRK1A and RCAN1 to
push hyperphosphorylation of tau as a consequence of DS genetic
defects in a GSK3β-independent manner (Fig. 7).Acknowledgements
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